GlassScriptPhysician profile
Conrad L Brimhall
NPI 1598740532
$15,326.65
in general payments reported to CMS, 2019-2025
39 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $1,199 · 2021: $1,705 · 2022: $2,360 · 2023: $2,425 · 2024: $3,153 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,016 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,015.55 |
| Education | $476.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,641.31 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $1,745.26 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,564.26 | 2019-2025 | |
| Janssen Biotech, INC. | $1,336.64 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,180.85 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,165.42 | 2020-2025 | Ilumya, Odomzo, Blu-U |
| Genentech USA, INC. | $665.15 | 2019-2023 | Erivedge |
| Novo Nordisk INC | $621.84 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $610.03 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $512.52 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $303.73 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $300.00 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $284.26 | 2024-2025 | Acthar |
| Amgen INC. | $266.87 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $259.25 | 2020-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Brimhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.